Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy.
BACKGROUND: To compare the incidence and timing of toxicity associated with the use of a reduced dose of stavudine from 40 to 30 mg in first-line antiretroviral therapy (ART) for HIV treatment and to investigate associated risk factors